ALB and neoplasm: Although the use of an albumin binder with lower affinity—such as p-(tolyl)butyric acid [11]—could improve the tumor-to-background ratios of [177Lu]Lu-DOTA-IPB-NAPamide, the optimization of the unexpectedly high non-target uptake of the 177Lu-labeled derivative is part of future work.